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Background. Cells treated with hsp90 inhibitors exhibit pleiotropic changes, including an expansion of the mitochondrial
compartment, accompanied by mitochondrial fragmentation and condensed mitochondrial morphology, with ultimate
compromise of mitochondrial integrity and apoptosis. Findings. We identified several mitochondrial oxidative phosphor-
ylation complex subunits, including several encoded by mtDNA, that are upregulated by hsp90 inhibitors, without
corresponding changes in mRNA abundance. Post-transcriptional accumulation of mitochondrial proteins observed with hsp90
inhibitors is also seen in cells treated with proteasome inhibitors. Detailed studies of the OSCP subunit of mitochondrial F1F0-
ATPase revealed the presence of mono- and polyubiquitinated OSCP in mitochondrial fractions. We demonstrate that
processed OSCP undergoes retrotranslocation to a trypsin-sensitive form associated with the outer mitochondrial membrane.
Inhibition of proteasome or hsp90 function results in accumulation of both correctly targeted and retrotranslocated
mitochondrial OSCP. Conclusions. Cytosolic turnover of mitochondrial proteins demonstrates a novel connection between
mitochondrial and cytosolic compartments through the ubiquitin-proteasome system. Analogous to defective protein folding
in the endoplasmic reticulum, a mitochondrial unfolded protein response may play a role in the apoptotic effects of hsp90 and
proteasome inhibitors.
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INTRODUCTION
Hsp90 is an abundant cytosolic chaperone (1–2% of cytosolic
protein) involved in the turnover, trafficking and activity of a large
number and variety of client proteins. These include membrane-
associated and soluble protein kinases (many recognized as
oncogenes) and transcription factors [1,2]. Small molecule hsp90
inhibitors that bind to the N-terminal ATP binding pocket inhibit
chaperone function. Consequently, many client proteins are
targeted for degradation via the ubiquitin-proteasome pathway.
In response to hsp90 inhibition, cancer cell lines exhibit several
types of response, including reversal of transformation, differen-
tiation and apoptosis [3–5]. Selective cytotoxicity for cancer cells is
associated with expression of hsp90 client proteins, such as Bcr-
Abl, FLT3 bearing an internal tandem duplication, and ErbB2,
and has been suggested to reflect a survival requirement for
multiple signaling pathways that depend on hsp90 chaperone
function [6–9]. Apoptotic cell death in hsp90-inhibited cells
involves mitochondrial pathways with cytosolic accumulation of
cytochrome c and SMAC/Diablo [10].
As an early event in cells destined for apoptosis, hsp90 inhibitors
induce mitochondrial proliferation, resulting in the accumulation of
a fragmented network of mitochondria filled with homogeneous,
electron-dense material obscuring the internal cristae [11,12].
Expansion of the mitochondrial compartment is associated with
reduced mitochondrial membrane potential (DYM), pointing to
a possible defect in mitochondrial biogenesis. Furthermore,
mitochondria isolated from cells treated with hsp90 inhibitors
stimulate nuclear condensation in cell-free apoptosis assays.
Unlike most of the known cytoplasmic clients of hsp90, we
demonstrate that mitochondrial proteins accumulate in cancer cells
treated with hsp90 inhibitors. Mitochondrial protein upregulation
occurs at a post-transcriptional level, and similar changes in
mitochondrial ultrastructure and mitochondrial protein expression
are exhibited in cancer cells treated with proteasome inhibitors.
Furthermore, we demonstrate that the F1F0-ATPase OSCP subunit
undergoes hsp90-dependent ubiquitination and has an increased
protein half-life in hsp90-inhibited cells. This process of organellar
protein turnover is reminiscent of endoplasmic reticulum associated
degradation (ERAD), which functions both as a quality control and
a regulatory pathway for ER proteins [13,14].
Hsp90-regulated degradation of mitochondrial proteins repre-
sents a novel and unexpected pathway in overall cellular economy.
Accumulation of mitochondrial proteins leading to intra-organel-
lar protein folding stress may be an early and important event in
cells treated with hsp90 or proteasome inhibitors for triggering
mitochondrial apoptosis pathways.
RESULTS
Hsp90 inhibition triggers mitochondrial protein
accumulation
COLO 205 colon cancer cells treated with hsp90 inhibitors,
including herbimycin A (HA), 17-allylamino-17-demethoxygelda-
namycin (17-AAG) and radicicol, undergo terminal differentiation
and apoptotic cell death within 72–96 h, preceded by dramatic
changes to the mitochondrial compartment or chondriome [11]
(Fig. 1 A and data not shown). Both the number of mitochondrial
Academic Editor: Debbie Fox, The Research Institute for Children, United States
of America
Received June 13, 2007; Accepted September 28, 2007; Published October 24,
2007
Copyright:  2007 Margineantu et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This work was supported by NIH (RO1 grant # 104402) and Amgen
Interdisciplinary Fellowship Fund.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: dhockenb@fhcrc.org
PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1066profiles and mitochondrial mass per cell, assessed by flow
cytometry of cells stained with nonyl acridine orange, increased at
24–72 h of treatment with hsp90 inhibitors (Fig. 1 B–D and data not
shown). Electron micrographs (EM) demonstrate that, in hsp90
inhibitor-treated cells, the mitochondrial matrix becomes pro-
gressively opacified with electron-dense material, and by 48 h the
internal cristal membranes are completely obscured (Fig. 2A, B).
Increased mitochondrial matrix density can be due to a loss of
water and ions (condensed conformation), but also may represent
increased matrix protein content [15]. Mild pronase treatment of
EM sections removed the electron-dense matrix material,
consistent with its proteinaceous nature (Fig. 2C, D). Mitochon-
drial fractions were prepared for protein quantitation at various
times after addition of hsp90 inhibitor. Total mitochondrial
protein (normalized to cell number) increased two-fold after 48 h
of treatment with HA or radicicol (Fig. 2E). Mitochondrial protein
normalized to mitochondrial volume per cell (estimated by the
summed area of EM mitochondrial profiles) also appeared to
increase after HA treatment (Fig. 2F).
We next determined whether expression of individual mito-
chondrial proteins changed in cells treated with hsp90 inhibitors
(Fig. 3A). Immunoblots demonstrated that subunits of cytochrome
c oxidase (COX I, III, IV, Vb), F1F0-ATPase (Complex V a,d ,
OSCP), and Complex III (Core 2), as well as cytochrome c, were
upregulated with HA treatment. Mitochondrial proteins targeted
to the outer mitochondrial membrane (VDAC) and matrix
(pyruvate dehydrogenase E1a) also accumulated in HA-treated
cells. Several electron transport chain subunits (Complex I 39 and
30 kD, Complex II 70 kD, and Complex V b) were not induced,
indicating that hsp90 inhibition produced selective changes to the
mitochondrial proteome (Fig. 3A). Protein expression levels of
three non-mitochondrial proteins, proliferating cellular nuclear
antigen (PCNA), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and tubulin, did not change in HA-treated cells.
Similar increases in mitochondrial protein expression were
observed with another hsp90 inhibitor, 17-AAG (Fig. 3B) and
a second cell line, 143B osteosarcoma cells (Fig. 3C).
To investigate the level of regulation of mitochondrial protein
expression in hsp90 inhibitor-treated cells, we performed Northern
blots for mRNAs representing nuclear and mtDNA-encoded
mitochondrial proteins (Fig. 4A). Neither mRNAs for chromo-
somal genes (COX IV (COX4), ATPase a (ATP5A), and OSCP
(ATP5O)) nor the mtDNA gene COX I (COI) encoding proteins
upregulated by hsp90 inhibitors were induced by HA treatment
(Fig. 4A, B). In addition, mtDNA copy number did not increase
with HA treatment (Fig. 4C). Thus, hsp90 inhibitors increase
expression of several mitochondrial proteins via post-transcrip-
tional regulation.
Ubiquitination and proteasomal degradation of
mitochondrial proteins
We next examined mitochondrial protein synthesis and turnover in
hsp90 inhibitor-treated cells.
35S-methionine/cysteine pulse-chase
labeling followed by immunoprecipitation of the nuclear-encoded
F1F0-ATPaseOSCPsubunitrevealed anincrease inproteinhalf-life
from 36–48 h in untreated cells to greater than 48 h in HA-treated
cells (Fig. 5A, B). No differences were observed in initial
35S-labeling
of OSCP between untreated and HA-treated cells. Therefore, the
increase in mitochondrial OSCP protein expression following hsp90
inhibition is due to reduced protein turnover.
Hsp90 co-purifies with mitochondria in COLO 205 cells, but
dissociates after treatment with hsp90 inhibitors (Fig. 5C). In
addition to a direct role in stability of client proteins, hsp90 also
functions in protein turnover mediated by the chaperone-de-
pendent ubiquitin E3 ligase, CHIP [16]. To determine whether
ubiquitin-dependent protein turnover affects the mitochondrial
compartment, we treated COLO 205 cells with proteasome
inhibitors. Condensed mitochondrial morphology and increased
mitochondrial mass developed within 24 h of treatment with
Figure 1. Colo-205 cells treated with Hsp90 inhibitors exhibit increased mitochondrial mass and apoptotic cell death. (A) Apoptosis measured by
Annexin V/ PI staining at 72 h of herbimycin A treatment (0.5 mM). B) Mitochondrial mass assessed by NAO staining for (B) 17-AAG (0.4 mM, 24 h), (C)
HA (0.5 mM, 48 h), (D) radicicol (1.5 mM, 72 h). Control (filled) vs. treated (empty) histograms.
doi:10.1371/journal.pone.0001066.g001
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(Fig. 6). Immunoblot analysis showed increased expression of the
same mitochondrial proteins (COX I, III, IV, OSCP, Complex
V-alpha) with two different proteasomal inhibitors, MG132 and
MG232, as seen with 17-AAG treatment (Fig. 7A). In contrast,
Raf-1, a known hsp90 client protein, is degraded in cells treated
with 17-AAG but accumulated in cells treated with proteasome
inhibitors.
Hsp90 and proteasome inhibitors can cause ER protein folding
stress and modulate the unfolded protein response (UPR) [17,18].
Figure 2. Mitochondrial protein accumulation with hsp90 inhibition. Transmission electron micrographs of control (A) and treated (B) COLO 205
cells (HA, 0.5 mM, 48 h) demonstrating increased number of mitochondrial profiles with dense matrix substance. Ultrathin sections from HA-treated
COLO 205 cells (0.5 mM, 48 h) with no protease treatment (C) and after pronase digestion (D). Arrows indicate mitochondrial profiles. (E) Protein
quantitation in mitochondrial fractions from 10
6 COLO 205 cells treated with HA (0.5 mM) or radicicol (1.5 mM), normalized to untreated cells; average
of three experiments, standard error,
# P=0.079, * P,0.05, ** P,0.005 for comparison to untreated cells. (F) Mitochondrial protein/10
6 cells
normalized to average total area of mitochondrial profiles/cell for control and HA-treated (0.5 mM, 48 h) COLO 205 cells. (P,0.05).
doi:10.1371/journal.pone.0001066.g002
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ER protein folding stress, we treated OSCP-GFP expressing 143B
cells with tunicamycin, an inducer of the ER UPR. OSCP-GFP
proteinlevelsdidnotincreaseincellstreatedwtihtunicamycin,while
in combination with 17-AAG, tunicamycin reduced mitochondrial
protein accumulation compared with 17-AAGalone(Figure S1).We
also tested inhibitors of autophagy for effects on mitochondrial
protein expression in COLO 205 cells. Treatment with two different
lysosomal inhibitors, monensin and chloroquine, or a macroauto-
phagy inhibitor, 3-methyladenine (3-MA) did not increase mito-
chondrial protein expression at 24 h (Fig. 7 A, B).
We next investigated whether proteasomal functions were
directly involved in turnover of mitochondrial proteins. Purified
mitochondria were prepared from a 10,0006g pellet fraction of
COLO 205 cell lysates by fractionation on a continuous iodixanol
gradient (19–27%). Anti-ubiquitin immunoblotting recognized
a high molecular weight smear in mitochondrial extracts from
untreated cells, consistent with polyubiquitinated species (Fig. 8A).
Mitochondria prepared from cells treated with HA or MG132 had
reduced amounts of ubiquitinated proteins. Ubiquitin immuno-
reactive bands were sensitive to trypsin digestion of intact
mitochondria, but mitochondrial association was retained in
0.1 M sodium carbonate (pH 11.5), suggesting that ubiquitinated
proteins are either tightly bound to the mitochondrial surface or
inserted in the outer mitochondrial membrane (OMM) (Fig. 8B).
Digitonin extracts of OMM also contained high molecular mass
ubiquitinated bands, although a greater proportion remained
associated with the mitoplast fraction (Fig. 8C).
Immunoprecipitation of OSCP from cellular extracts recovered
a broad smear at ,80–180 kD size and a 30 kD band in addition
to the expected 21 kD band representing mature OSCP. Sub-
sequent immunoblotting with an anti-ubiquitin antibody recog-
nized the 80–180 kD and 30 kD species, but not the 21 kD band,
consistent with poly- and mono-ubiquitinated OSCP (Fig. 8D).
OSCP immunoprecipitates from cells treated with HA exhibited
only a 21 kD band, with no reactivity on anti-ubiquitin
immunoblots. In view of the effect of proteasome inhibitors on
OSCP protein expression, these results are consistent with
ubiquitin-mediated OSCP turnover. Furthermore, hsp90 appears
to be required for the attachment of ubiquitin to OSCP.
Figure 3. Changes in specific mitochondrial protein expression in response to hsp90 inhibition. Western blots from control and treated cells at 0,
24, 48 and 72 h. 4610
4 cell equivalents were loaded in each lane. COLO-205 cells treated with HA (0.5 mM) (A) or 17-AAG (0.4 mM ) (B). (C) 143B cells
treated with HA (0.5 mM). PCNA, GAPDH and a-tubulin were used as loading controls. For each panel, proteins above the line are upregulated with
hsp90 inhibitor treatment, and proteins below the line have stable expression.
doi:10.1371/journal.pone.0001066.g003
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1066Figure 4. Hsp90 inhibitors affect mitochondrial protein expression at a post-transcriptional level. (A) Northern blots of mtDNA gene COI and
nuclear genes COX4, ATP5A, and ATP5O in COLO 205 cells treated with HA (0.5 mM). 18S rRNA was used as loading control. (B) Quantitation of
Northern blots by densitometry normalized to 18S rRNA levels. (C) Southern blot hybridized with mtDNA (CytB and ND2) and nuclear DNA gene
(ATP5C) probes.
doi:10.1371/journal.pone.0001066.g004
Figure 5. Hsp90 inhibition increases mitochondrial protein stability. (A) Immunoprecipitation of pulse-chase [
35S]-labeled OSCP subunit from
control and HA (0.5 mM) treated cells. HA was added to cells at the time of pulse labeling. Total OSCP protein is demonstrated by Western blotting in
lower panel. (B) Densitometry of the OSCP autoradiography signal is graphed. (C) Mitochondrial localization of hsp90 in COLO 205 cells and response
to HA (0.5 mM) and MG132 (0.5 mM) treatment for 48 h. Mitochondrial VDAC expression increases with both treatments.
doi:10.1371/journal.pone.0001066.g005
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proteins
OSCP is a component of the F1F0-ATP synthase complex
localized to the mitochondrial matrix, physically separated from
cytoplasmic ubiquitin ligases. To address whether imported
mitochondrial OSCP was susceptible to proteasomal degradation,
we stably expressed an OSCP-GFP fusion protein in 143B cells.
OSCP-GFP is efficiently imported to the mitochondrial matrix
[19]. Proteasome and hsp90 inhibitors increased expression of
OSCP-GFP, as well as the endogenous OSCP protein (Fig. 9A).
Monitoring of GFP fluorescence intensity by flow cytometry
provided results similar to immunoblot analysis (Fig. 9B-top
panel). To isolate effects on imported mitochondrial OSCP-GFP,
we treated cells with the uncoupling agent CCCP to prevent new
DYM-dependent import of matrix-targeted proteins prior to
adding proteasome or hsp90 inhibitors. CCCP treatment of
143B-OSCP-GFP cells decreased GFP fluorescence, as expected
[20]. Even so, treatment with MG132 or HA increased OSCP-
GFP expression in cells pre-treated with CCCP, as shown by
immunoblot and flow cytometry, with a mitochondrial localization
determined by fluorescence microscopy (Fig. 9A–C). These results
Figure 6. Proteasome inhibition results in increased mitochondrial mass and matrix condensation. Transmission electron micrograph of (A)
control and (B) MG132-treated COLO 205 cells (0.5 mM MG132, 24 h). (C) Flow cytometric assay of mitochondrial mass by NAO staining. COLO 205
cells treated with MG132 (0.5 mM). Control (filled) vs treated (empty) histograms.
doi:10.1371/journal.pone.0001066.g006
Figure 7. Mitochondrial protein expression in COLO 205 cells treated with Hsp90, proteasomal and lysosomal inhibitors. (A,B) Western blots of
cell lysates after treatment with indicated inhibitors for 24 h. Inhibitor concentrations: 17-AAG (0.2, 0.4 mM), MG132 (0.25, 0.5 mM), MG262 (0.05,
0.1 mM), monensin (0.25, 0.5 mM), chloroquine (25, 50 mM), 3-MA (5 mM). Extracts from 2–4610
4 cells were loaded per lane.
doi:10.1371/journal.pone.0001066.g007
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PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e1066Figure 8. Mitochondria of COLO 205 cells contain ubiquitinated proteins. Anti-ubiquitin Western blots: (A) iodixanol gradient-purified
mitochondria from control, HA- (0.5 mM, 48 h), and MG132-treated cells (0.5 mM, 24 h). VDAC signal is shown for loading control. (B) mitochondria
after incubation with trypsin (5–30 min) or 0.1 M Na2CO3. TX-Triton X-100 (1%); P-pellet, S-supernatant, control blots of OMM-associated protein
(hexokinase II); (C) OMM and mitoplast mitochondrial fractions after digitonin extraction. (D) Western blots of immunoprecipitated OSCP from COLO
205 cell extracts-control (C) and 48 h HA (0.5 mM) treatment.
doi:10.1371/journal.pone.0001066.g008
Figure 9. Hsp90 and proteasome inhibitors increase OSCP levels post-mitochondrial import. (A) Western blots of 143B cells transfected with
OSCP-GFP and treated with HA (0.5 mM), MG132 (0.5 mM), and CCCP (10 mM) for 18 h. (B) Flow cytometry histograms of GFP fluorescence after 18 h
of treatment. Top panel, filled histogram: control; open histograms: HA (light grey), MG-132 (dark grey). Middle panel, filled histogram: control; open
histogram: CCCP; Bottom panel, filled histogram: CCCP; open histograms: CCCP+HA (light grey), CCCP+MG-132 (dark grey). (C) Fluorescence
micrographs of GFP fluorescence in cells treated with HA, CCCP or CCCP plus HA for 24 h.
doi:10.1371/journal.pone.0001066.g009
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of the OSCP subunit after mitochondrial import.
In an established model of organellar protein turnover by
ubiquitin-mediated proteasomal degradation, endoplasmic reticu-
lum-associated degradation (ERAD), endoplasmic reticulum
proteins are exported to the cytoplasm in a process termed
retro-translocation. We questioned whether a similar process could
operate for mitochondrial proteins. ERAD retro-translocation
intermediates can be trapped by inhibition of downstream
proteasomal processing [21–24]. We analyzed the localization of
OSCP in mitochondrial membrane fractions before and after
treatment with proteasome inhibitors. Sub-mitochondrial frac-
tionation demonstrated the expected distribution for OSCP in
mitoplasts (inner mitochondrial membrane and matrix) isolated
from control cells (Fig. 10A). The abundant outer mitochondrial
membrane protein VDAC is incompletely extracted by digitonin,
presumably due to its association with contact sites between inner
and outer mitochondrial membranes [25]. However, in cells
treated with HA or MG132, a substantial proportion of the mature
21 kD OSCP is associated with the OMM. Notably, removal of
the OSCP transit peptide occurs in the mitochondrial matrix,
implying that export is required for the appearance of the 21 kD
OSCP protein in the OMM fraction. A smaller amount of COX II
appears in the OMM fraction from treated cells, suggesting that
mtDNA-encoded proteins may also be exported.
In order to detect dynamic retro-translocation, we pulse-labeled
cells with
35S-methionine/cysteine and examined mitochondrial
import of OSCP by immunoprecipitation from mitochondrial
fractions. In parallel, mitochondria were treated with trypsin to
degrade OSCP associated with the OMM. The percentage of
trypsin-resistant
35S-labeled mitochondrial OSCP increased dur-
ing the first 4 h of chase, reflecting mitochondrial import of newly
synthesized protein (Fig. 10B). However, after an additional 4 h
chase period, the percentage of OSCP that was trypsin-sensitive
increased in mitochondrial fractions, consistent with retro-trans-
location of previously imported protein.
Regulation vs quality control
Ubiquitin-mediated proteasomal degradation of ER proteins
provides a mechanism for regulating protein expression as well
as quality control of protein folding. To examine the effect of
hsp90-regulated mitochondrial protein turnover on assembly of
a multi-protein electron transport complex in COLO 205 cells, we
solubilized mitochondrial membranes in dodecyl maltoside de-
tergent and analyzed complex assembly by centrifugation on
a sucrose density gradient [26]. Immunoblots were performed on
collected fractions for individual cytochrome c oxidase subunits
(Fig. 11). In untreated COLO 205 cells, COX I and COX II
exhibit a broad peak centered at fraction 5, while COX IV has
two peaks, one in fraction 5 coincident with COX I/II, and
a second peak at lower density in fraction 8. In cells treated with
hsp90 inhibitor, a unimodal distribution of COX IV is observed,
with disappearance of the low density peak. These results suggest
that inhibition of hsp90-regulated turnover of mitochondrial
proteins can promote assembly of respiratory chain complexes,
consistent with a regulatory function. Although oxygen consump-
tion in COLO-205 cells treated with HA is only ,35% of control
cells, maximal respiration rates in the presence of the uncoupler
CCCP, are identical for treated and untreated cells, suggesting
that the total respiratory capacity is maintained for a significant
period, in agreement with the complex assembly data (Figure S2).
In its quality control function, ERAD extracts microsomal
proteins as part of the UPR. We observed a consistent reduction in
the amount of mitochondrial protein extractable with nonionic
detergents in cells treated with hsp90 inhibitors (Fig. 12A). Taking
into account the increase in total (SDS-extractable) mitochondrial
protein in HA-treated cells, the amount of Triton X-100 insoluble
mitochondrial protein increased more than three-fold after 48 h of
HA treatment.
We surmised that the dense mitochondrial matrix observed in
electron micrographs of cells treated with proteasome or hsp90
inhibitors could represent aggregated or unfolded protein. In order
Figure 10. Recovery of inner mitochondrial membrane proteins OSCP and COX II in OMM fraction in cells treated with hsp90 and proteasome
inhibitors. Western blots of whole mitochondria (WM), digitonin-extracted OMM and mitoplast (MP) fractions from COLO 205 cells treated with HA
(0.5 mM, 48 h) and MG132 (0.5 mM, 24 h). (B) Immunoprecipitable [
35S]-pulse-labeled mitochondrial OSCP after trypsin treatment of mitochondria,
representative of two experiments.
doi:10.1371/journal.pone.0001066.g010
Figure 11. Improved cytochrome c oxidase assembly in HA-treated
cells. Western blot of sucrose gradient density fractions of mitochon-
drial protein complexes; fraction 1 to 10 decreases in density.
doi:10.1371/journal.pone.0001066.g011
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cells prior to extraction in low concentrations of non-ionic
detergent, followed by processing for electron microscopy. Control
COLO 205 cells exhibited empty mitochondrial profiles consistent
with complete extraction of mitochondrial matrix proteins with up
to 1 h of pre-fixation (Fig. 12B). In contrast, mitochondrial matrix
proteins in HA-treated cells were completely resistant to Triton X-
100 extraction with as little as 15 min of pre-fixation (Fig 12C).
Thus, one consequence of mitochondrial protein accumulation in
cells treated with hsp90 inhibitors is a change in protein solubility,
with potentially negative consequences for mitochondrial function.
DISCUSSION
Hsp90 inhibitors induce apoptosis, with selectivity for cancer cells,
via mitochondrial pathways. Analysis of the mitochondrial
compartment, using mitochondrially targeted fluorescent probes
and electron microscopy, revealed early increases in mitochondrial
mass, associated with distinctive ultrastructural changes, in cells
treated with hsp90 inhibitors. To investigate the basis of these
changes, we analyzed mitochondrial protein expression. We
identified an increase in total mitochondrial protein, normalized
to cell number, as well as multiple individual mitochondrial
proteins in COLO 205 and 143B cells treated with hsp90
inhibitors, including nuclear-encoded (COX IV, Vb, F1F0-
ATPase a, d, OSCP, cytochrome c, VDAC1, PDH E1a) and
mtDNA-encoded respiratory complex subunits (COX I, III).
Notably, several other respiratory complex subunits examined
were unaffected. We excluded transcriptional regulation for
several of these proteins by the stable steady state levels of cognate
cytosolic and mitochondrial mRNAs and mtDNA copy number.
Unexpectedly, ATP5A and ATP5O mRNAs declined after 48 and
72 h of HA treatment (Fig. 4). This may represent a retrograde
response (mitochondria-to-nuclear signaling) to the increased
mitochondrial mass.
Pulse-chase studies demonstrated that the mitochondrial F1F0-
ATPase OSCP subunit is stabilized in hsp90-inhibited cells.
Treatment with proteasome inhibitors MG132 and MG262, but
not lysosomal (monensin, chloroquine) or autophagy (3-methylade-
nine) inhibitors, produced a similar pattern of mitochondrial protein
upregulation in COLO 205 cells, suggesting that proteasomal
protein degradation pathways are involved in mitochondrial protein
turnover. We next demonstrated that immunoprecipitation of
OSCP from purified mitochondrial lysates isolated several slower
migrating bands recognized by anti-ubiquitin immunoblots and
consistent with mono- and poly-ubiquitinated OSCP, in addition to
the mature 21 kD OSCP. This result is consistent with direct
proteasomal degradation of a mitochondrial protein, mediated via
poly-ubiquitin conjugation. Furthermore, hsp90 inhibition sup-
pressed the recovery of ubiquitin-modified OSCP in mitochondrial
lysates, suggesting hsp90 is required for effective interaction of
mitochondrial OSCP with one or more ubiquitin ligases.
The ubiquitin-proteasome system is not previously known to
participate in the turnover of mitochondrial proteins. However,
several proteomic efforts to catalogue ubiquitin-modified proteins
have identified mitochondrial proteins including respiratory chain
subunits residing in the inner mitochondrial membrane and
matrix (see Table 1). A recent analysis of the mouse heart
ubiquitinated proteome shows that proteins localized in mito-
chondria represent a major fraction (38 %) and expands the list of
the ubiquitin conjugated mitochondrial proteins [33]. Proteasomal
turnover of the mitochondrial heme synthetic enzyme 5-
aminolevulinic acid synthase 2 was demonstrated [34]. The
prominent 30 kD band consistent with monoubiquitinated OSCP,
could represent an intermediate product in polyubiquitination, or
carry out a separate role in protein trafficking, lysosomal
degradation, or protein interactions [35].
Proteasome and hsp90 inhibitors increased the expression and
mitochondrial fluorescence of an OSCP-GFP fusion protein, even
Figure 12. Mitochondrial proteins in HA-treated cells are resistant to detergent extraction. (A) Recovery of mitochondrial protein in lysis buffer
with 0.5% Triton X-100 compared to CHAPS-Urea (HA 0.5 mM). * P,0.05. (B, C) Electron micrographs of mitochondria following glutaraldehyde pre-
fixation and Triton X-100 extraction for control (B) and HA-treated COLO 205 cells (C). Mitochondria are indicated by arrows.
doi:10.1371/journal.pone.0001066.g012
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..................................................................................................................................................
Protein Protein Hu Sc Ar Biological Process Reference
1 NADH dehydrogenase (ubiquinone) NDI1 X oxidative phosphorylation [27]
2 Succinate dehydrogenase cytochrome B560 subunit C560_HUMAN X oxidative phosphorylation [28]
3 Succinate dehydrogenase cytochrome b SDH3 X oxidative phosphorylation [27]
4 Succinate dehydrogenase (ubiquinone) activity (Sdh1p homolog) YJL045W X oxidative phosphorylation [27]
5 Ubiquinol cytochrome c reductase complex Core 2 Protein UCR2_HUMAN X oxidative phosphorylation [28]
6 8.5 kDa subunit of the ubiqunol-cytochrome c oxidoreductase
complex
QCR10 X oxidative phosphorylation [27]
7 Ubiquinol cytochrome-c reductase subunit 8 QCR8 X oxidative phosphorylation [27]
8 Ubiquinol-cytochrome c reductase AT4G32470.1 X oxidative phosphorylation [29]
9 Cytochrome c1 CYT1 X X oxidative phosphorylation [27], [29]
10 Subunit VII of cytochrome c oxidase COX7 X oxidative phosphorylation [27]
11 Cytochrome oxidase assembly factor COX15 X oxidative phosphorylation [27]
12 Modulates cytochrome c oxidase activity COX13 X oxidative phosphorylation [27]
13 F1F0-ATP synthase alpha subunit ATP1 X X oxidative phosphorylation [28], [30],
[31]
14 F1F0-ATP syntahse beta subunit ATPB_HUMAN X oxidative phosphorylation [28], [30]
15 F1F0-ATP synthase B chain, mitoch. precursor ATPF_HUMAN X oxidative phosphorylation [28]
16 F1F0-ATP synthase gamma chain, mitochondrial ATPC X oxidative phosphorylation [29]
17 Protein associated with mitochondrial ATP synthase TIM11 X oxidative phosphorylation [27]
18 Cytochrome c CYC_HUMAN X oxidative phosphorylation [28]
19 Iso-2-cytochrome c CYC7 X oxidative phosphorylation [27]
20 Plant uncoupling mitochondrial protein PUMP X oxidative phosphorylation [29]
21 Malate dehydrogenase precursor MDHM_HUMAN X X tricarboxylic acid cycle [28], [29],
[30]
22 Isocitrate dehydrogenase precursor IDHA_HUMAN X tricarboxylic acid cycle [30]
23 Dihydrolipoamide dehydrogenase (E3) precursor DLDH_ HUMA X tricarboxylic acid cycle [28], [30]
24 Aconitase hydratase ACON_HUMAN X tricarboxylic acid cycle [30]
25 Citrate synthase CIT1 X tricarboxylic acid cycle [27]
26 Alpha-ketoglutarate dehydrogenase KGD1 X tricarboxylic acid cycle [27]
27 Alpha subunit of succinyl-CoA ligase LSC1 X tricarboxylic acid cycle [27]
28 Beta subunit of succinyl-CoA ligase LSC2 X tricarboxylic acid cycle [27]
29 Pyruvate dehydrogenase E1 component alpha subunit AT1G59900.1 X tricarboxylic acid cycle [29]
30 Pyruvate dehydrogenase E1 component beta subunit AT5G50850.1 X tricarboxylic acid cycle [29]
31 2-oxoglutarate dehydrogenase E1 AT3G55410.1 X tricarboxylic acid cycle [29]
32 Acetyl-CoA carboxylase ACC1 X fatty acid biosynthesis [27], [31]
33 Trifunctional enzyme FAS2 X fatty acid biosynthesis [27], [31]
34 Aspartate aminotransferase precursor AATM_HUMAN X aminoacid metabolism [30]
35 Required for the translation of OLI1 mRNA. AEP2 X protein biosynthesis [27]
36 Mitochondrial and cytoplasmic valyl-tRNA synthetase VAS1 X valine-tRNA ligase [27]
37 5-aminolevulinate synthase HEM1 X hem metabolism [27]
38 Protein involved in mitochondrial iron accumulation MMT2 X iron metabolism [27]
39 Oxodicarboxylate carrier ODC1 X mitochondrial transport [27]
40 The major mitochondrial ADP/ATP translocator PET9 X mitochondrial transport [27], [31]
41 Mitochondrial substrate carrier family protein AT4G01100.1 X mitochondrial transport [29]
42 Phosphate carrier protein, mitochondrial precursor MPCP_HUMAN X mitochondrial transport [28]
43 Voltage-dependent anion selective channel protein 2 POR2_HUMAN X X mitochondrial transport [28], [29]
44 Translocase of the outer mitochondrial membrane TOM5 X mitochondrial translocation [27]
45 Translocase of the outer mitochondrial membrane TOM7 X mitochondrial translocation [27]
46 Translocase of outer mitochondrial membrane, 70 kDa OM70_HUMAN X X mitochondrial translocation [27]
47 Mitochondrial import receptor subunit Tom22 homolog OM22_HUMAN X mitochondrial translocation [28]
47 Translocase of the inner membrane TIM50 X mitochondrial translocation [27]
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PLoS ONE | www.plosone.org 10 October 2007 | Issue 10 | e1066in the presence of a protonophore causing collapse of mitochon-
drial membrane potential, DYM. Mitochondrial import of matrix-
targeted proteins, including OSCP, is DYM-dependent, implying
that these inhibitors affect the turnover of previously imported
mitochondrial OSCP. Ubiquitin-conjugated proteins in mitochon-
drial fractions are tightly associated with the outer mitochondrial
membrane as shown by digitonin extraction, protease susceptibil-
ity, and resistance to alkali extraction. These results are analogous
to protein ubiquitination in endoplasmic reticulum associated
degradation (ERAD), where both soluble and membrane inserted
ER proteins undergo retro-translocation before ubiquitin conju-
gation at the cytosolic face of the ER [13,14].
Mitochondrial subfractionation demonstrated a shift in locali-
zation of mature OSCP to the OMM in cells treated with hsp90 or
proteasome inhibitors. This likely represents a retro-translocation
intermediate, as observed for several ERAD substrates [21–24],
and suggests that hsp90 function and proteasome activity are
required, at least in part, for complete retro-translocation. Hsp90
co-purified with COLO 205 mitochondria, although the associ-
ation was diminished in HA- and MG132-treated cells. TRAP1,
a mitochondrial paralog of hsp90, is also inhibited by the tested
hsp90 inhibitors [36,37]. Knockdown of TRAP1 expresssion using
TRAP1 short-hairpin RNAs did not affect responses to 17-AAG,
although basal expression levels for several mitochondrial proteins
were diminished consistent with the postulated role of TRAP1 as
an intramitochondrial chaperone (Figure S3).
Hsp90 is reported to function in protein degradation, in
addition to its role in protein folding, via its association with
CHIP, an E3 ubiquitin ligase [16]. Reduction of CHIP protein
expression by 60–90% by shRNA-mediated RNA interference did
not result in increased mitochondrial protein expression or
suppress responses to 17-AAG (Figure S3), raising the possibility
of alternative E3-ligases, perhaps recognizing processed mitochon-
drial proteins as N-end rule substrates, as hsp90 co-factors. Hsp90
may also facilitate transport of ubiquitin-conjugated OSCP to the
proteasome. Hsp90 inhibition leads to an increase in insoluble
ubiquitinated cytosolic proteins [38].
Mitochondrial proteins can also be degraded in a nonselective
manner via autophagy, or more specifically, mitophagy. Autophagic
degradation of organelles and bulk cytosolic components is
physiologically activated during nutrient starvation to maintain an
adequatesupplyofnutrientsforcellsurvival.Inhibitionofautophagy
with 3-MA or inhibition of lysosomal activity with monensin or
chloroquine did not lead to increased mitochondrial protein
expression in COLO 205 cells grown in standard media. In contrast,
3-MA increased OSCP-GFP expression in cells grown under
nutrient starvation conditions [39] (Figure S4). Our data suggests
thathsp90 and the26Sproteasomeare componentsofan alternative
pathway for selective degradation of mitochondrial proteins.
Increased mitochondrial protein expression in cells treated with
hsp90 inhibitors was associated with improved cytochrome oxidase
assembly, but ultimately led to an increase in detergent-insoluble
mitochondrial proteins, and mitochondrial dysfunction [11].
Analogous to defective protein folding in the endoplasmic reticulum,
a mitochondrial unfolded protein response may play a role in the
apoptotic effects of hsp90 and proteasome inhibitors [40].
MATERIALS AND METHODS
Cell lines
COLO 205 cells were grown as described [11]. 143B cells were
grown in High Glucose-Dulbecco’s Minimal Essential Medium
with 10% fetal bovine serum in 10% CO2. Amino-acid deprived
medium was cysteine/methionine-free HG- DMEM. 143B cells
Table 1. cont.
Protein Protein Hu Sc Ar Biological Process Reference
49 Mitochondrial 28S ribosomal protein S33 RT33_HUMAN X mitochondrial nucleic acid
metabolism
[28]
50 Mitochondrial elongation factor EFGM_ARATH X mitochondrial nucleic acid
metabolism
[29]
51 Mitochondrial transcription termination factor AT5G23930.1 X mitochondrial nucleic acid
metabolism
[29]
52 Cytochrome b reductase CBR1 X electron transport [27]
53 Hypothetical ORF NDE1 X ethanol fermentation [27]
54 Hypothetical ORF NDE2 X ethanol fermentation [27]
55 Involved in receptor-mediated endocytosis and mitochondrial
organization
DNM1 X mitochondrion organization and
biogenesis
[27]
56 Protein involved in mitochondrial fusion FZO1 X mitochondrion organization and
biogenesis
[27], [31]
57 Putative hemolysin-like protein with three transmembrane
domains
MAM3 X mitochondrion organization and
biogenesis
[27]
58 Mitochondrion organization and biogenesis MDM38 X mitochondrion organization and
biogenesis
[27]
59 Mitochondrion inheritance MDM10 X mitochondrion inheritance [27]
60 Cytoskeleton organization and biogenesis MDM20 X cytoskeleton organization and
biogenesis
[27]
61 Stress-70 (mitochondrial) GR75_HUMAN X chaperone [28]
62 Prohibitin PHB_HUMAN X X chaperone [29], [32]
63 Smac protein, mitochondrial precursor SMAC_HUMAN X apoptosis [28]
Hu–Homo Sapiens; Sc.–Saccharomyces cerevisiae;A r – Arabidopsis Thaliana.
doi:10.1371/journal.pone.0001066.t001
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PLoS ONE | www.plosone.org 11 October 2007 | Issue 10 | e1066were transfected with pEGFP-N1 vector (BD Biosciences) bearing
a full length human OSCP cDNA in frame with a COOH-
terminal GFP sequence, using Fugene6 Transfection Reagent
(Roche). Individual clones were obtained after selection in
100 mg/ml G418.
Reagents and Antibodies
All chemicals were purchased from Sigma-Aldrich with the
exception of MG262 and Tunicamycin (Calbiochem). Herbimycin
A, 17-AAG and radicicol (Sigma) were dissolved in DMSO at
1 mg/ml and stored in aliquots at 270uC. MG132 and MG262
were prepared as 1 mM stocks in DMSO and stored at 270uC.
Monensin was prepared as a 1 mM stock in ethanol, and
chloroquine (50 mM) and 3-MA (250 mM) were dissolved in
H20 and stored at 4uC. Tunicamycin was dissolved in DMSO
(20 mM) and stored at 220uC. Monoclonal antibodies against
mitochondrial respiratory chain proteins were obtained from
MitoSciences Inc. Other antibodies used: VDAC (PC548,
Oncogene), pyruvate dehydrogenase E1alpha subunit (A-21323,
Invitrogen), cytochrome c (556433, BD Biosciences), c-Raf
(610151, BD Biosciences), CHIP/STUB1 (IMG-3137, Imgenex),
PCNA (NA03, Oncogene), GAPDH (ab8245, Abcam), tubulin
(CP06-100UG, Oncogene), hexokinase (sc-6521, Santa Cruz
Biotechnology), ubiquitin (sc-8017, Santa Cruz; 550944, BD
Biosciences), Hsp90 (sc-7947, Santa Cruz).
Flow cytometry
For nonyl acridine orange (NAO) staining, cells were resuspended
in phosphate-buffered saline (PBS) at 1610
6 cells/ml and
incubated with 1 nM NAO for 10 min at room temperature in
the dark. Cells were analyzed on a FACScan cytometer (Becton
Dickinson). Annexin V binding and propidium iodide (PI) staining
was performed according to manufacturer’s protocol (Annexin
V:FITC Apoptosis Detection Kit II, BD Biosciences).
Electron microscopy
Transmission electron microscopy was performed as described
[41]. To address the nature of the dense mitochondrial matrix
material, ultrathin sections of cell pellets embedded in water-
soluble media were incubated with 1 mg/ml pronase at 37uC for
1 h. Cells were pre-fixed for various times (15 min, 30 min or 1 h)
in 0.25% glutaraldehyde, exposed to 0.25% Triton X-100 in PBS
for 15 min and post-fixed in half strength Karnovsky’s fixative.
Transmission electron micrographs were taken using a Jeol 1010
transmission electron microscope operating at 80 kV. The 2D
area of mitochondrial profiles was calculated from transmission
electron micrographs using Image J (NIH). Profiles were traced in
sets of 10 cells (6,000x magnification) for control and HA-
treatment. The mitochondrial area was summed for each cell to
derive an average total mitochondrial area per cell, calculated in
mm
2 after correction by the magnification factor.
Western blotting
Whole cell lysates were prepared from 5610
6 cells/ml resus-
pended in lysis buffer (1% n-dodecyl b-D maltoside, 25 mM
Hepes pH 7.2, 200 mM NaCl, 5 mM EDTA plus protease
inhibitors) on ice for 30 min. Soluble proteins were separated from
insoluble material by centrifugation at 18,000x g for 20 min at
4uC. Protein extracts were denatured in 1X Laemmli buffer
supplemented with 10 mM dithiothreitol (DTT) at 37uC for
30 min, loaded on SDS-polyacrylamide gels and separated by
electrophoresis in Tris-Glycine buffer at 100 V. Proteins were
transferred to 0.2 mM PVDF membranes (Millipore) in CAPS
buffer for 2 h at 200 mA or overnight at 40 V. Membranes were
blocked in 5% fat free milk in phosphate-buffered saline with
0.05% Tween-20 (PBST) for 1 h at room temperature, incubated
with primary antibody overnight at 4uC and with secondary
antibodies (goat anti-mouse or goat anti-rabbit conjugated to
horseradish peroxidase) for 2 h at room temperature. Signal was
developed by chemiluminescence (ECL Plus, GE Healthcare).
Southern and Northern blot analysis
Total genomic DNA extracted from cells was digested with NcoI
(Promega), separated with 1X TAE (40 mM Tris, 20 mM acetic
acid, 1 mM EDTA) running buffer on a 0.7% agarose gel, and
transferred to nitrocellulose (Zeta-Probe, Bio-Rad). Southern blots
were hybridized to [a-
32P]-labeled probes generated by random
priming. Final wash steps were performed with 0.1xSSC and 0.1%
SDS at 65uC. RNA isolation and Northern analysis was performed
as described [41]. I.M.A.G.E. clones used to obtain probes for
Southern and Northern blotting: ND2: 5581341, CytB: 4257731,
COI: 5139968, COX4: 68531, ATP5A: 3355758, ATP5C: 647125,
ATP5O: 5551187. Southern blots were performed in duplicate and
Northern blots in triplicate. Hybridization signals from a repre-
sentative Northern blot were quantitated using ImageJ (NIH) and
normalized to 18S rRNA levels.
Mitochondrial preparations
Cells were disrupted either by nitrogen cavitation (500 psi for
10 min) or 10–15 passages through a 25G needle inhomogenization
buffer (0.25 M sucrose, 1 mM EGTA, 10 mM HEPES, 0.5 %
bovine serum albumin, pH 7.4, with protease inhibitors). Mitochon-
drial pellets were obtained from post-nuclear supernatant by
centrifugation at 10,0006g. For some studies, mitochondria were
purified by centrifugation on a continuous 19–27% iodixanol
gradient (Optiprep) for 2 h at 70,0006g. Alkali extraction was
performed with 0.1 M Na2CO3 for 30 min on ice; trypsin digestion
(50 mg/ml) was performed at 37uC.Outermitochondrial membrane
(OMM) preparations were obtained by digitonin (1 mg/mg protein)
extraction for 20 min. Sucrose gradient fractionation of respiratory
chain complexes was performed as described [26].
Immunoprecipitation
The F1F0-ATPase OSCP subunit was immunoprecipitated from
cells lysed in TENT buffer (0.5% Triton X-100, 50 mM Tris-HCL,
150 mM NaCL, 5 mM EDTA, pH 7.4 with freshly added protease
inhibitors) at 4uC. After centrifugation at 12,0006g for 15 min to
remove insoluble material, the extracts were incubated overnight at
4 ˚C with anti-OSCP antibody cross-linked to Protein G Sepharose
beads (Amersham Biosciences), washed three times with TENT
buffer, and eluted with 100 mM glycine, pH 2.8. Eluted proteins
were neutralized with 1 M Tris pH 8.0, denatured at 65uCf o r
10 min in 1X Laemmli buffer with 10 mM fresh DTT, and
separated by 4–15% gradient SDS-PAGE for Western blotting.
For pulse-chase studies, cells were plated 24 h before labeling
with 50 mCi/ml [
35S]-methionine/cysteine (Trans label, ICN) in
met/cys-free medium. For trypsin sensitivity of mitochondrial
OSCP, cells were pulse-labeled for 2 h and then chased in the
presence of cycloheximide 100 mg/ml. Mitochondrial suspensions
were prepared at each time point (from 8610
6 cells). One-half of
each sample was incubated with trypsin 50 mg/ml for 20 min at
37uC, followed by immunoprecipitation of OSCP from TENT
extracts of trypsin-treated and untreated mitochondria. Gels were
fixed for 30 min at room temperature in 40% methanol, 10%
acetic acid, and 5% glycerol, followed by incubation in Amplify
Fluorographic Reagent (GE Healthcare), gel drying and exposure
Mitochondrial Protein Turnover
PLoS ONE | www.plosone.org 12 October 2007 | Issue 10 | e1066to phosphor storage screens (Molecular Dynamics). Autoradio-
graph images (Typhoon 8600, GE Healthcare) were analyzed
using ImageQuant software.
Differential solubility of mitochondrial proteins
Mitochondrial fractions (50 mg protein) were extracted in TENT
buffer for 30 min at 4 ˚C. Soluble proteins were recovered by
centrifugation for 30 min at 20,0006g. The insoluble pellet was
dissolved in CHAPS-Urea (8M urea, 2% CHAPS, 150 mM NaCl,
5 mM EDTA, 10 mM Tris pH 7.4) at room temperature. Protein
concentration of TENT-soluble and insoluble fractions was
measured by Bradford assay (Bio-Rad).
Fluorescence microscopy
143B cells expressing OSCP-GFP fusion protein were grown on
glass coverslips and treated with 0.5 mM HA, 20 mM CCCP, or
both for 24 h. Cells were fixed in 4% paraformaldehyde and
mounted on slides for fluorescence imaging (Nikon Eclipse E800,
100X Plan Fluor objective). Photomicrographs of cells subjected to
different treatments were acquired during the same experimental
session with identical exposure times.
RNA interference
Short-hairpin sequences against CHIP (STUB1) and TRAP1
genes were cloned into the lentiviral vector pLKO.1-TRC
(Addgene). The target sequences selected are: CHIP sh1 59-
GCACGACAAGTACATGGCGGA -39[42]; CHIP sh3: 59-
GAAGAGGAAGAAGCGAGACAT-39 (The RNAi Consortium
#TRCT0000001576); TRAP1 sh1: 59- ACCGTCCATGTTT-
GATGTGAG-39; TRAP1sh2: 59- GTACAGCAACTTCGT-
CAGC-39 [30]; TRAP1sh3: 59-GCGCTCATCAAGAAGCT-
GAAT-39 (The RNAi Consortium #TRCN0000060676).
Viral particles were obtained by co-transfection of 293T cells
with the pLKO.1-shRNA, envelope (pMD2G) and packaging
(pCMVdR8.74) vectors. 143B and OSCP-GFP 143B cells were
transduced with the shRNA lentivirus and selected in puromycin
at 1 mg/ml. Control cells were transduced with virus carrying
a scrambled shRNA sequence (pLKO.1-scramble shRNA; Ad-
dgene). CHIP and TRAP1 mRNA expression levels were
determined by quantitative real-time PCR using the Brilliant
SYBR Green Master Mix (Stratagene). Expression was normalized
to actin. CHIP protein expression was confirmed by Western
blotting.
Oxymetry
Colo 205 cells were harvested with trypsin, resuspended in
respiration buffer (125 mM KCl, 2 mM K2HPO4, 1 mM MgCl2,
5 mM K-Hepes, pH 7, 1 mM EGTA, 5 mM glutamate, 5 mM
malate) at 2610
7 cells/ml and allowed to equilibrate for 5 min
before loading in the electrode chamber (Oxytherm, Hansatech
Instruments). Cells were stirred at 37uC during O2 consumption
measurements. After obtaining a stable respiration rate, CCCP
(10 mM) was added to uncouple respiration and determine
maximal O2 consumption rates.
Statistics
Statistical analysis was done using Student’s paired t-test. The data
are expressed as means6standard error and statistical significance
was indicated by P,0.05.
SUPPORTING INFORMATION
Figure S1 Endoplasmic reticulum stress induced by tunicamycin
does not cause OSCP-GFP accumulation. Flow cytometry
histograms of OSCP-GFP fluorescence after 24 h of treating
143-B cells with tunicamycin (A) 20 mM; (B) 100 mM; (C) 17-AAG
(0.4 mM); (D) tunicamycin (100 mM) and 17-AAG (0.4 mM).
Found at: doi:10.1371/journal.pone.0001066.s001 (0.04 MB TIF)
Figure S2 Oxygen consumption rates of control COLO 205 and
herbimycin A (0.5 mM) treated-COLO 205 cells at 48 h. Coupled
versus uncoupled (10 mM) respiration. P,0.005 for coupled
respiration.
Found at: doi:10.1371/journal.pone.0001066.s002 (0.04 MB TIF)
Figure S3 Downregulation of TRAP1 or CHIP expression does
not affect the response to 17-AAG. Quantitative real-time PCR
data for CHIP and TRAP1 mRNA expression in control 143B
cells, cells transduced with scrambled, CHIP (A) or TRAP1 (B)
shRNA. Expression is normalized to b-actin levels. (C) Western
blot of CHIP protein expression in control cells and cells
transduced with CHIP shRNA1, CHIP shRNA3 or scrambled
shRNA. (D) Western blots showing accumulation of OSCP and
COXIII protein with 17-AAG treatment in control and shRNA
expressing cells. Tubulin was used as loading control. Flow
cytometry histograms of GFP expression with cells expressing
scrambled shRNA (E), TRAP1 shRNA3 (F), CHIP shRNA1 (G),
CHIP shRNA3 (H). Control-gray profile; 17-AAG treatment
(0.4 mM, 24 hours)-black profile.
Found at: doi:10.1371/journal.pone.0001066.s003 (0.08 MB TIF)
Figure S4 Regulation of OSCP-GFP protein levels by hsp90
and proteasome inhibitors in complete and amino acid-deficient
media. Flow cytometry histograms of GFP fluorescence in 143B
cells transfected with OSCP-GFP. Cells were treated with 17-AAG
(0.4 mM), MG-132 (1 mM), or 3-MA (5 mM) for 24 h. The
autophagy inhibitor 3-MA has an effect on mitochondrial protein
expression only in amino acid-deficient media (methionine/
cysteine-free medium).
Found at: doi:10.1371/journal.pone.0001066.s004 (0.06 MB TIF)
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